BPMC Blueprint Medicines Corp
1,709
$105.56
$0.80
(0.75%)
| Watchers | 1,709 |
| 52-Wk Low | $43.89 |
| 52-Wk High | $111.02 |
| Market Cap | $6.61B |
| Volume | 631,490.00 |
| 52-Wk High | $111.02 |
| 52-Wk Low | $43.89 |
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT (avapritinib)PR Newswire • 1 day ago
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT (avapritinib) Blueprint Medicines Announces Data...
Share to Feed
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO...
Latest Ratings for BPMC
DateFirmActionFromTo Mar 2022StifelMaintainsBuy Mar 2022CitigroupInitiates Coverage OnNeutral Feb 2022SVB LeerinkDowngradesOutperformMarket Perform
View More Analyst...
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass...
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance Blueprint Medicines Reports Strong First Quarter 2024 Results and...
Latest Ratings for BPMC
DateFirmActionFromTo Mar 2022StifelMaintainsBuy Mar 2022CitigroupInitiates Coverage OnNeutral Feb 2022SVB LeerinkDowngradesOutperformMarket Perform
View More Analyst...
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 PR Newswire...
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics Blueprint Medicines to Host Webcast and Conference Call Highlighting...
Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are covering the company, MarketBeat.com reports...
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass...